Axsome Therapeutics has delivered a very large 5 year share price gain, yet the stock has pulled back sharply in recent months. That mix of long term gains and recent weakness puts a simple question in front of you as an investor: is today's valuation justified by the sales the business is generating? Over the past 5 years, Axsome Therapeutics shares have returned about 237.2%, so a lot of optimism is already baked into the price that now needs to be weighed against the company's sales...
A late-stage pipeline with 10 programs in development offers multiple growth catalysts beyond Auvelity's current commercial momentum.
Motley Fool Press Release.
Axsome (AXSM) delivered earnings and revenue surprises of +63.77% and +5.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI® 3Q 2026 net product revenue of $48.2 million, representing 47% year-over-year growth SYMBRAVO® 3Q 2026 net product sales of $3.9 million, representing 88% year-over-year growth SUMMIT Phase 3 trial of AXS-05 for smoking cessation initiated Company to host conference call today at 8:00 AM Eastern Time NEW
Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size.
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These drugmakers are capitalizing on their pipeline successes.
AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.
Detailed price information for Axsome Thera (AXSM-Q) from The Globe and Mail including charting and trades.
Find the latest Axsome Therapeutics, Inc. (19X.F) stock quote, history, news and other vital information to help you with your stock trading and investing.
Auvelity's Alzheimer's expansion could transform Axsome by 2030.
Detailed price information for Axsome Thera (AXSM-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.